Pharmacogenetics implementation in the clinics: information and guidelines for germline variants

Area of Science:

• Pharmacogenetics
• Oncology
• Clinical Practice

Background:

• Germline pharmacogenetics offers personalized cancer treatment strategies.
• Implementing pharmacogenetic testing in clinical settings requires robust evidence and guidelines.

Purpose of the Study:

• To provide an overview of germline pharmacogenetics applicable to oncology clinical practice.
• To explain the essential criteria for selecting genetic polymorphisms for clinical use.

Main Methods:

• Reviewed PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations (levels 1-2).
• Assessed genetic information from major drug regulatory agencies (FDA, EMA).
• Examined guidelines from international expert consortia (CPIC, DPWG).

Main Results:

• Identified key genetic polymorphisms relevant for clinical implementation.
• Compiled recommendations for applying pharmacogenetic test results in oncology.

Conclusions:

• Established a framework for integrating germline pharmacogenetics into routine cancer care.
• Highlighted the importance of evidence-based resources for guiding clinical decisions.